Skip to main content
. Author manuscript; available in PMC: 2017 Jul 26.
Published in final edited form as: Biochem Soc Trans. 2016 Apr 15;44(2):412–418. doi: 10.1042/BST20150291

Figure 1. Armored CAR T-cells genetically engineered to constitutively secrete IL-12.

Figure 1

CAR T-cells modified to secrete IL-12 improve CAR T anti-tumour efficacy by potentially modulating the tumour microenvironment via autocrine activity on CAR T-cells, suppression of Treg cells, reprogramming of tumour-associated macrophages and enhanced IL-12 production by DCs.